Patent application number | Description | Published |
20130025281 | GASIFICATION SYSTEM AND METHOD - A system configured for the production of at least one product selected from the group consisting of syngas, Fischer-Tropsch synthesis products, power, and chemicals, the system comprising a dual fluidized bed gasification apparatus and at least one apparatus selected from power production apparatus configured to produce power from the gasification product gas, partial oxidation reactors configured for oxidation of at least a portion of the product gas, tar removal apparatus configured to reduce the amount of tar in the product gas, Fischer-Tropsch synthesis apparatus configured to produce Fischer-Tropsch synthesis products from at least a portion of the product gas, chemical production apparatus configured for the production of at least one non-Fischer-Tropsch product from at least a portion of the product gas, and dual fluidized bed gasification units configured to alter the composition of the product gas. Methods of operating the system are also provided. | 01-31-2013 |
20130028801 | GASIFICATION SYSTEM AND METHOD - A system configured for the production of at least one product selected from the group consisting of syngas, Fischer-Tropsch synthesis products, power, and chemicals, the system comprising a dual fluidized bed gasification apparatus and at least one apparatus selected from power production apparatus configured to produce power from the gasification product gas, partial oxidation reactors configured for oxidation of at least a portion of the product gas, tar removal apparatus configured to reduce the amount of tar in the product gas, Fischer-Tropsch synthesis apparatus configured to produce Fischer-Tropsch synthesis products from at least a portion of the product gas, chemical production apparatus configured for the production of at least one non-Fischer-Tropsch product from at least a portion of the product gas, and dual fluidized bed gasification units configured to alter the composition of the product gas. Methods of operating the system are also provided. | 01-31-2013 |
20130028802 | GASIFICATION SYSTEM AND METHOD - A system configured for the production of at least one product selected from the group consisting of syngas, Fischer-Tropsch synthesis products, power, and chemicals, the system comprising a dual fluidized bed gasification apparatus and at least one apparatus selected from power production apparatus configured to produce power from the gasification product gas, partial oxidation reactors configured for oxidation of at least a portion of the product gas, tar removal apparatus configured to reduce the amount of tar in the product gas, Fischer-Tropsch synthesis apparatus configured to produce Fischer-Tropsch synthesis products from at least a portion of the product gas, chemical production apparatus configured for the production of at least one non-Fischer-Tropsch product from at least a portion of the product gas, and dual fluidized bed gasification units configured to alter the composition of the product gas. Methods of operating the system are also provided. | 01-31-2013 |
20130030062 | GASIFICATION SYSTEM AND METHOD - A system configured for the production of at least one product selected from the group consisting of syngas, Fischer-Tropsch synthesis products, power, and chemicals, the system comprising a dual fluidized bed gasification apparatus and at least one apparatus selected from power production apparatus configured to produce power from the gasification product gas, partial oxidation reactors configured for oxidation of at least a portion of the product gas, tar removal apparatus configured to reduce the amount of tar in the product gas, Fischer-Tropsch synthesis apparatus configured to produce Fischer-Tropsch synthesis products from at least a portion of the product gas, chemical production apparatus configured for the production of at least one non-Fischer-Tropsch product from at least a portion of the product gas, and dual fluidized bed gasification units configured to alter the composition of the product gas. Methods of operating the system are also provided. | 01-31-2013 |
20130030064 | GASIFICATION SYSTEM AND METHOD - A system configured for the production of at least one product selected from the group consisting of syngas, Fischer-Tropsch synthesis products, power, and chemicals, the system comprising a dual fluidized bed gasification apparatus and at least one apparatus selected from power production apparatus configured to produce power from the gasification product gas, partial oxidation reactors configured for oxidation of at least a portion of the product gas, tar removal apparatus configured to reduce the amount of tar in the product gas, Fischer-Tropsch synthesis apparatus configured to produce Fischer-Tropsch synthesis products from at least a portion of the product gas, chemical production apparatus configured for the production of at least one non-Fischer-Tropsch product from at least a portion of the product gas, and dual fluidized bed gasification units configured to alter the composition of the product gas. Methods of operating the system are also provided. | 01-31-2013 |
20160002547 | GASIFIER FLUIDIZATION - A system for the production of synthesis gas, including a gasification apparatus configured to convert at least a portion of a gasifier feed material introduced thereto into a gasification product gas comprising synthesis gas having a molar ratio of hydrogen to carbon monoxide; at least one additional apparatus selected from the group consisting of feed preparation apparatus located upstream of the gasification apparatus, synthesis gas conditioning apparatus, and synthesis gas utilization apparatus; and at least one line fluidly connecting the at least one additional apparatus or an outlet of the gasification apparatus with the at least one vessel of the gasification apparatus, whereby a gas from the at least one additional apparatus or exiting the gasification apparatus may provide at least one non-steam component of a fluidization gas. A method of utilizing the system is also provided. | 01-07-2016 |
Patent application number | Description | Published |
20130105008 | SEAL POT DESIGN | 05-02-2013 |
20130109765 | GASIFIER FLUIDIZATION | 05-02-2013 |
20130161563 | SUPPLEMENTAL FUEL TO COMBUSTOR OF DUAL FLUIDIZED BED GASIFIER - A method of gasification by introducing a feed material to be subjected to gasification into a dual fluidized bed gasifier comprising a pyrolyzer fluidly connected with a combustor such that a circulation stream comprising a heat transfer material can be continuously circulated between the pyrolyzer, in which the temperature of the circulation stream is reduced, and the combustor, in which the temperature of the circulation stream is increased, wherein the pyrolyzer is operable to convert at least a portion of the feed material into a gasifier product gas comprising hydrogen and carbon monoxide, and wherein the combustor is operable to increase the temperature of the circulation stream via combustion of char introduced thereto with the circulation stream and at least one supplemental fuel. A system for carrying out the method is also provided. | 06-27-2013 |
20130165534 | SYSTEM AND METHOD FOR PRODUCTION OF FISCHER-TROPSCH SYNTHESIS PRODUCTS AND POWER - A method for generation of power and Fischer-Tropsch synthesis products by producing synthesis gas comprising hydrogen and carbon monoxide, producing Fischer-Tropsch synthesis products and Fischer-Tropsch tailgas from a first portion of the synthesis gas, and generating power from a second portion of the synthesis gas, from at least a portion of the Fischer-Tropsch tailgas, or from both. The method may also comprise conditioning at least a portion of the synthesis gas and/or upgrading at least a portion of the Fischer-Tropsch synthesis products. A system for carrying out the method is also provided. | 06-27-2013 |
20140037509 | SUPPLEMENTAL FUEL TO COMBUSTOR OF DUAL FLUIDIZED BED GASIFIER - A method of gasification by introducing a feed material to be subjected to gasification into a dual fluidized bed gasifier comprising a pyrolyzer fluidly connected with a combustor such that a circulation stream comprising a heat transfer material can be continuously circulated between the pyrolyzer, in which the temperature of the circulation stream is reduced, and the combustor, in which the temperature of the circulation stream is increased, wherein the pyrolyzer is operable to convert at least a portion of the feed material into a gasifier product gas comprising hydrogen and carbon monoxide, and wherein the combustor is operable to increase the temperature of the circulation stream via combustion of char introduced thereto with the circulation stream and at least one supplemental fuel. A system for carrying out the method is also provided. | 02-06-2014 |
20140161676 | SEAL POT DESIGN - An apparatus including at least one seal pot having at least one penetration through a surface other than the top of the seal pot, each of the at least one penetrations being configured for introduction, into the at least one seal pot, of solids from a separator upstream of the at least one seal pot; a substantially non-circular cross section; or both at least one penetration through a surface other than the top of the seal pot and a substantially non-circular cross section. | 06-12-2014 |
20150232769 | GASIFICATION SYSTEM AND METHOD - A method including introducing a carbonaceous feedstock and a heated heat transfer material into a gasifier, whereby at least a portion of the carbonaceous material is pyrolyzed; removing a gasification product gas comprising, entrained therein, char, particulate heat transfer material, and optionally unreacted carbonaceous feedstock; separating a solids product comprising char, heat transfer material and optionally unreacted carbonaceous material from the gasification product gas; heating at least a portion of the solids product via a combustor, thus producing a heated portion of the solids product and a combustor flue gas, wherein a portion of the heat for heating is obtained via combustion of the char; separating the heated portion from the flue gas, and introducing the separated heated portion into the gasifier, providing heat for pyrolysis; and utilizing at least a portion of the gasification product gas for Fischer-Tropsch synthesis and/or power production. | 08-20-2015 |
Patent application number | Description | Published |
20120141484 | METHODS OF PREVENTING INFLAMMATION AND TREATING PAIN USING ANTI-NGF COMPOSITIONS - Monovalent agents, including Fab fragments and monovalent monoclonal antibodies analogous to MetMab, having binding specificity to human Nerve Growth Factor (“NGF”), and methods treating pain in an individual wherein there is no substantial increase in the inflammatory response of the individual following administration of the monovalent agents. | 06-07-2012 |
20120141485 | METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES - Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA.) | 06-07-2012 |
20120148490 | ANTI-NGF COMPOSITIONS AND USE THEREOF - The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 06-14-2012 |
20120164067 | METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES THAT SELECTIVELY INHIBIT THE ASSOCIATION OF NGF WITH TRKA, WITHOUT AFFECTING THE ASSOCIATION OF NGF WITH P75 - NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA. | 06-28-2012 |
20120294797 | ANTI-CGRP COMPOSITIONS AND USE THEREOF - The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 11-22-2012 |
20130034554 | ANTIBODIES TO IL-6 AND USE THEREOF - The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. Additional preferred embodiments of the subject invention relate to therapeutic compositions and methods treating or preventing rheumatoid arthritis, especially subcutaneous and intravenous formulations and dosage regimens using IL-6 antagonists according to the invention, as well as methods for preventing or treating GVHD or leukemia relapse in subjects receiving transplanted cells, tissue or organs, use thereof in the treatment or prevention of mucositis, and use thereof to potentiate the cytotoxic, apoptotic, and anti-metastatic or anti-invasive effects of chemotherapeutics and radiation on cancers, especially cancers that have developed a resistance to radiation or chemotherapy, such as an EGFR inhibitor. | 02-07-2013 |
20130224201 | ANTIBODIES TO IL-6 AND USE THEREOF - The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. | 08-29-2013 |
20130302399 | ANTI-PCSK9 ANTIBODIES AND USE THEREOF - The present invention is directed to antibodies and fragments thereof having binding specificity for PCSK9. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 11-14-2013 |
20130336975 | ANTI-NGF COMPOSITIONS AND USE THEREOF - The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 12-19-2013 |
20130344068 | METHODS OF PREVENTING INFLAMMATION AND TREATING PAIN USING ANTI-NGF COMPOSITIONS - This invention pertains to monovalent agents, including Fab fragments and monovalent monoclonal antibodies analogous to MetMab, having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain in an individual wherein there is no substantial increase in the inflammatory response of the individual following administration of the monovalent agents. | 12-26-2013 |
20140004115 | METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES THAT SELECTIVELY INHIBIT THE ASSOCIATION OF NGF WITH TRKA, WITHOUT AFFECTING THE ASSOCIATION OF NGF WITH P75 | 01-02-2014 |
20140004116 | METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES | 01-02-2014 |
20140271459 | ANTIBODIES TO HGF AND COMPOSITIONS CONTAINING - The present invention is directed to antibodies and fragments thereof having binding specificity for HGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 09-18-2014 |
20140271464 | THERAPEUTIC USE OF ANTIBODIES TO HGF - The present invention is directed to antibodies and fragments thereof (especially chimeric and humanized) having binding specificity for HGF and their use in therapy and diagnosis. These antibodies inhibit or block HGF-associated activities including HGF's effects on cell proliferation, invasion, angiogenesis, metastasis and fibrosis. Particularly the antibodies may be used as a monotherapy or in combination therapies in treating cancer, other proliferative disorders and other conditions wherein inhibition of HGF and/or the HGF/HGF-R (c-met) interaction is desired. | 09-18-2014 |
20140271664 | THERAPEUTIC USE OF ANTIBODIES TO HGF - The present invention is directed to antibodies and fragments thereof (especially chimeric and humanized) having binding specificity for HGF and their use in therapy and diagnosis. These antibodies inhibit or block HGF-associated activities including HGF's effects on cell proliferation, invasion, angiogenesis, metastasis and fibrosis. Particularly the antibodies may be used as a monotherapy or in combination therapies in treating cancer, other proliferative disorders and other conditions wherein inhibition of HGF and/or the HGF/HGF-R (c-met) interaction is desired. | 09-18-2014 |
20140287952 | PROTOCOL FOR IDENTIFYING AND ISOLATING ANTIGEN-SPECIFIC B CELLS AND PRODUCING ANTIBODIES TO DESIRED ANTIGENS - Methods of identifying antigen-specific antibody-secreting and antibody-forming cells, such as antigen-specific B cells, and methods for cloning the antigen-specific antibody sequences of the antibody produced by these cells are provided. In particular, the methods include enriching B cells for antigen-specific B cells, culturing the antigen-specific B cells to generate clonal B cell populations, detecting clonal B cells that produce a single antigen-specific antibody, optionally screening the clonal B cell populations for functional activity, staining and sorting the cells to isolate the antigen-specific B cells, sequencing the nucleic acids encoding the antigen-specific antibody sequences, expressing the sequences to produce an antibody, isolating the antibody and screening the antibody for antigen recognition. The methods provide improved enrichment and selection of antigen-specific antibody-secreting and antibody-forming cells, which enhances recovery of antigen-specific antibodies. | 09-25-2014 |
20150132224 | ANTIBODIES TO IL-6 AND USE THEREOF - The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 05-14-2015 |
20150132304 | METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES THAT SELECTIVELY INHIBIT THE ASSOCIATION OF NGF WITH TRKA, WITHOUT AFFECTING THE ASSOCIATION OF NGF WITH P75 - NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA. | 05-14-2015 |
20150197567 | ANTIBODIES TO IL-6 AND USE THEREOF - The present invention is directed to antibodies and fragments thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 07-16-2015 |
20150259413 | ANTIBODIES TO IL-6 AND USE THEREOF - The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 09-17-2015 |
20150259414 | ANTI-ACTH ANTIBODIES AND USE THEREOF - The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the V | 09-17-2015 |
20150274823 | ANTIBODIES TO IL-6 AND USE THEREOF - The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 10-01-2015 |
20150322145 | THERAPEUTIC USE OF ANTIBODIES TO HGF - The present invention is directed to antibodies and fragments thereof (especially chimeric and humanized) having binding specificity for HGF and their use in therapy and diagnosis. These antibodies inhibit or block HGF-associated activities including HGF's effects on cell proliferation, invasion, angiogenesis, metastasis and fibrosis. Particularly the antibodies may be used as a monotherapy or in combination therapies in treating cancer, other proliferative disorders and other conditions wherein inhibition of HGF and/or the HGF/HGF-R (c-met) interaction is desired. | 11-12-2015 |
20150329625 | METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES - Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA.) | 11-19-2015 |
20150337035 | ANTIBODIES TO TNF ALPHA AND USE THEREOF - The present invention is directed to antibodies and fragments thereof having binding specificity for TNF-α. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 11-26-2015 |
20150337036 | ANTIBODIES TO IL-6 AND USE THEREOF - The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other cogulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. | 11-26-2015 |
20150368330 | METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES THAT SELECTIVELY INHIBIT THE ASSOCIATION OF NGF WITH TRKA, WITHOUT AFFECTING THE ASSOCIATION OF NGF WITH P75 - This invention pertains to NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA. | 12-24-2015 |